Insider Buying: Predictive Oncology Inc. (NASDAQ:POAI) Director Purchases 159,500 Shares of Stock

Predictive Oncology Inc. (NASDAQ:POAIGet Rating) Director J Melville Engle bought 159,500 shares of Predictive Oncology stock in a transaction dated Tuesday, May 24th. The stock was acquired at an average price of $0.37 per share, with a total value of $59,015.00. Following the acquisition, the director now directly owns 203,393 shares of the company’s stock, valued at $75,255.41. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Shares of NASDAQ:POAI traded down $0.02 during midday trading on Tuesday, hitting $0.36. 67,597 shares of the stock were exchanged, compared to its average volume of 756,341. Predictive Oncology Inc. has a 52-week low of $0.25 and a 52-week high of $1.64. The business’s fifty day simple moving average is $0.79 and its two-hundred day simple moving average is $0.88. The company has a market capitalization of $23.74 million, a PE ratio of -1.23 and a beta of 1.57.

Predictive Oncology (NASDAQ:POAIGet Rating) last announced its quarterly earnings data on Thursday, March 31st. The medical instruments supplier reported ($0.06) earnings per share (EPS) for the quarter. The firm had revenue of $0.48 million for the quarter, compared to analysts’ expectations of $2.50 million. Predictive Oncology had a negative return on equity of 27.33% and a negative net margin of 1,314.56%. On average, analysts anticipate that Predictive Oncology Inc. will post -0.06 EPS for the current fiscal year.

A number of institutional investors have recently bought and sold shares of POAI. Virtu Financial LLC acquired a new stake in shares of Predictive Oncology in the first quarter valued at about $66,000. Charles Schwab Investment Management Inc. acquired a new stake in shares of Predictive Oncology in the first quarter valued at about $54,000. Renaissance Technologies LLC acquired a new stake in shares of Predictive Oncology in the fourth quarter valued at about $224,000. UBS Group AG grew its position in shares of Predictive Oncology by 411.2% in the third quarter. UBS Group AG now owns 18,788 shares of the medical instruments supplier’s stock valued at $25,000 after purchasing an additional 15,113 shares during the last quarter. Finally, Geode Capital Management LLC grew its position in shares of Predictive Oncology by 56.7% in the third quarter. Geode Capital Management LLC now owns 649,832 shares of the medical instruments supplier’s stock valued at $864,000 after purchasing an additional 235,127 shares during the last quarter. 6.23% of the stock is currently owned by hedge funds and other institutional investors.

Predictive Oncology Company Profile (Get Rating)

Predictive Oncology Inc, a knowledge-driven company, focuses on developing personalized cancer therapies using artificial intelligence (AI) primarily in the United States. The company operates in four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment offers clinical testing services comprising tumor drug response testing and genomic profiling tests; and contract research services through patient-centric drug discovery using active learning technology for discovery, clinical and translational research, clinical trials, and diagnostic development and validation.

See Also

Receive News & Ratings for Predictive Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Predictive Oncology and related companies with MarketBeat.com's FREE daily email newsletter.